Jefferies Global Healthcare Conference
Logotype for United Therapeutics Corporation

United Therapeutics (UTHR) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for United Therapeutics Corporation

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Commercial performance and outlook

  • Q3 revenue reached a record $833 million; TYVASO revenue also set a record at $504 million.

  • More than 1,000 referrals across the commercial portfolio in October set a new monthly record; management expects added sales teams to support Q4 and 2027 momentum.

TYVASO in PH-ILD

  • PH-ILD remains a key growth driver; management expects newly diagnosed patients to transition to TYVASO DPI as the settlement’s label and communication changes take effect, with momentum expected in Q4 and 2027.

  • Timing of payer coverage changes will vary by payer; management hopes updates align with the beginning-of-year reauthorization process.

  • Management plans close monitoring of settlement compliance and said it would act to protect its intellectual property if the agreed guardrails are not followed.

  • Management expressed comfort with current rebates but said it would assess the settlement’s prospective gross-to-net impact over time.

TYVASO in IPF

  • The FDA accepted the nebulized TYVASO sNDA for IPF, with a PDUFA date of April 26; management expects broad use and does not anticipate a price change.

  • TETON results were described as generalizable across subgroups and on background therapy; use could be adjunctive, refractory, or potentially first-line, guided by physician judgment and patient needs.

  • Payer discussions and Medicare local coverage determination work are ongoing; teams are preparing, with further progress expected in 2027 as the PDUFA date approaches.

  • European partner Ferrer filed with the EMA for nebulized TYVASO in IPF in the regions covered by its agreement.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from United Therapeutics